Defining and managing risk in asthma

Clinical and Experimental Allergy

Volumn 44, Issue 8, 2014, Pages 1023-1032

  Blakey, J D ^a   Zaidi, S ^b   Shaw, D E ^c  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; MEPOLIZUMAB; STEROID;

ARTICLE; ASTHMA; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; EOSINOPHIL COUNT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; LUNG FUNCTION; MEDICAL DECISION MAKING; MEDICATION THERAPY MANAGEMENT; MORBIDITY; PATHOPHYSIOLOGY; PATIENT ATTITUDE; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; RISK ASSESSMENT; RISK FACTOR; SUBCUTANEOUS IMMUNOTHERAPY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; DISEASE COURSE; DISEASE MANAGEMENT; PROGNOSIS; RISK;

ASTHMA; DISEASE MANAGEMENT; DISEASE PROGRESSION; HUMANS; PROGNOSIS; RISK;

EID: 84904626998     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12334     Document Type: Article

References (106)

1. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol 2007; 120(5 Suppl):S94-138.
2. Bousquet J, Mantzouranis E, Cruz AA et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010; 126:926-38.
3. Asher MI, Montefort S, Bjorksten B et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006; 368:733-43.
4. NHS. The_NHS_Information_Centre. Inpatient statistics, 2010-11. NHS, 2012. Available from: http://www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=1937&categoryID=202.
5. Tata LJ, West J, Harrison T, Farrington P, Smith C, Hubbard R. Does influenza vaccination increase consultations, corticosteroid prescriptions, or exacerbations in subjects with asthma or chronic obstructive pulmonary disease? Thorax 2003; 58:835-9.
6. Bai TR, Vonk JM, Postma DS, Boezen HM. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J 2007; 30:452-6.
7. James AL, Palmer LJ, Kicic E et al. Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking. Am J Respir Crit Care Med 2005; 171:109-14.
8. Sears MR, Greene JM, Willan AR et al. A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. N Engl J Med 2003; 349:1414-22.
9. Mori H, Tanaka H, Ohno Y et al. Effect of intermittent systemic corticosteroid on bone metabolism in bronchial asthma patients. J Asthma 2009; 46:142-6.
10. Cumming RG, Mitchell P. Inhaled corticosteroids and cataract: prevalence, prevention and management. Drug Saf 1999; 20:77-84.
11. Thomas M, Bruton A, Moffat M, Cleland J. Asthma and psychological dysfunction. Prim Care Respir J 2011; 20:250-6.
12. Health and Social Care Information Centre. Mortality from Asthma: Health and Social Care Information Centre, 2013.
13. Bahadori K, Doyle-Waters MM, Marra C et al. Economic burden of asthma: a systematic review. BMC Pulm Med 2009; 9:24.
14. Anderson HR, Gupta R, Strachan DP, Limb ES. 50 years of asthma: UK trends from 1955 to 2004. Thorax 2007; 62:85-90.
15. Wenzel S. Characteristics, definition and phenotypes of severe asthma. In: Chung KF, Bel E, Wenzel S, eds. ERS monograph: difficult-to-treat severe asthma. Vol. 51. European Respiratory Society. 2011.
16. British Thoracic Society and Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax 2008; 63(Suppl. 4):iv1-121.
17. Bateman ED, Hurd SS, Barnes PJ et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008; 31:143-78.
18. Nathan RA, Sorkness CA, Kosinski M et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004; 113:59-65.
19. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14:902-7.
20. Blakey JD, Woolnough K, Fellows J, Walker S, Thomas M, Pavord ID. Assessing the risk of attack in the management of asthma: a review and proposal for revision of the current control-centred paradigm. Prim Care Respir J 2013; 22:344-52.
21. Pavord I. Complex airway disease: an approach to assessment and management. Lancet Respir Med 2012; 1:84-90.
22. Griffiths C, Clark N. Predicting the risk of an asthma attack: the way ahead? Prim Care Respir J 2012; 21:368-70.
23. Edwards W. The theory of decision making. Psychol Bull 1954; 51:380-417.
24. Hall KH. Reviewing intuitive decision-making and uncertainty: the implications for medical education. Med Educ 2002; 36:216-24.
25. Slovic P. Perception of risk. Science 1987; 236:280-5.
26. Hertwig R, Pachur T, Kurzenhauser S. Judgments of risk frequencies: tests of possible cognitive mechanisms. J Exp Psychol Learn Mem Cogn 2005; 31:621-42.
27. Lichtenstein S, Slovic P, Fischhoff B, Layman M, Combs B. Judged frequency of lethal events. J Exp Psychol Hum Learn 1978; 4:551-78.
28. Spiegelhalter D. Micromorts. Available from: http://understandinguncertainty.org/micromorts2012.
29. Reddel HK, Taylor DR, Bateman ED et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180:59-99.
30. Thomas M, Gruffydd-Jones K, Stonham C, Ward S, Macfarlane TV. Assessing asthma control in routine clinical practice: use of the Royal College of Physicians '3 questions'. Prim Care Respir J 2009; 18:83-8.
31. Volbeda F, Broekema M, Lodewijk ME et al. Clinical control of asthma associates with measures of airway inflammation. Thorax 2013; 68:19-24.
32. Meltzer EO, Busse WW, Wenzel SE et al. Use of the Asthma Control Questionnaire to predict future risk of asthma exacerbation. J Allergy Clin Immunol 2011; 127:167-72.
33. Peters D, Chen C, Markson LE, Allen-Ramey FC, Vollmer WM. Using an asthma control questionnaire and administrative data to predict health-care utilization. Chest 2006; 129:918-24.
34. Buhl R, O'Byrne P, Humber M, Peterson S, Eriksson G. Patient baseline variables predict future asthma control status and risk of exacerbations. European Respiratory Society Annual Congress, 2010.
35. Lotvall J, Akdis CA, Bacharier LB et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011; 127:355-60.
36. Haldar P, Pavord ID, Shaw DE et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178:218-24.
37. Feldman JM, Kutner H, Matte L et al. Prediction of peak flow values followed by feedback improves perception of lung function and adherence to inhaled corticosteroids in children with asthma. Thorax 2012; 67:1040-5.
38. Gonem S, Raj V, Wardlaw AJ, Pavord ID, Green R, Siddiqui S. Phenotyping airways disease: an A to E approach. Clin Exp Allergy 2012; 42:1664-83.
39. Bateman ED, Reddel HK, Eriksson G et al. Overall asthma control: the relationship between current control and future risk. J Allergy Clin Immunol 2010; 125:600-8, 8 e1-8 e6.
40. Blakey JD, Wardlaw AJ. What is severe asthma? Clin Exp Allergy 2012; 42:617-24.
41. Romagnoli M, Caramori G, Braccioni F et al. Near-fatal asthma phenotype in the ENFUMOSA Cohort. Clin Exp Allergy 2007; 37:552-7.
42. Miller MK, Lee JH, Blanc PD et al. TENOR risk score predicts healthcare in adults with severe or difficult-to-treat asthma. Eur Respir J 2006; 28:1145-55.
43. Shaw D, Green R, Berry M et al. A cross-sectional study of patterns of airway dysfunction, symptoms and morbidity in primary care asthma. Prim Care Respir J 2012; 21:283-7.
44. Lucas AE, Smeenk FW, Smeele IJ, van Schayck CP. Overtreatment with inhaled corticosteroids and diagnostic problems in primary care patients, an exploratory study. Fam Pract 2008; 25:86-91.
45. Dennis S, Price JF, Vickers M, Frost CD, Levy ML, Barnes PJ. The management of newly identified asthma in primary care in England. Prim Care Respir J 2002; 11:120-2.
46. Robinson DS, Campbell DA, Durham SR, Pfeffer J, Barnes PJ, Chung KF. Systematic assessment of difficult-to-treat asthma. Eur Respir J 2003; 22:478-83.
47. Boulet LP, Franssen E. Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma. Respir Med 2007; 101:2240-7.
48. Yoon R, McKenzie DK, Bauman A, Miles DA. Controlled trial evaluation of an asthma education programme for adults. Thorax 1993; 48:1110-6.
49. Ni Chroinin M, Lasserson TJ, Greenstone I, Ducharme FM. Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev 2009:CD007949.
50. Pauwels RA, Lofdahl CG, Postma DS et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337:1405-11.
51. Bateman ED, Boushey HA, Bousquet J et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170:836-44.
52. Rank MA, Hagan JB, Park MA et al. The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol 2013; 131:724-9.
53. Price D, Haughney J, Sims E et al. Effectiveness of inhaler types for real-world asthma management: retrospective observational study using the GPRD. J Asthma Allergy 2011; 4:37-47.
54. de Vries F, Setakis E, Zhang B, van Staa TP. Long-acting {beta}2-agonists in adult asthma and the pattern of risk of death and severe asthma outcomes: a study using the GPRD. Eur Respir J 2010; 36:494-502.
55. Olesen JB, Lip GY, Hansen ML et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011; 342:d124.
56. Schmidt M, Jacobsen JB, Lash TL, Botker HE, Sorensen HT. 25 year trends in first time hospitalisation for acute myocardial infarction, subsequent short and long term mortality, and the prognostic impact of sex and comorbidity: a Danish nationwide cohort study. BMJ 2012; 344:e356.
57. Smolina K, Wright FL, Rayner M, Goldacre MJ. Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study. BMJ 2012; 344:d8059.
58. Skyler JS, Lasky IA, Skyler DL, Robertson EG, Mintz DH. Home blood glucose monitoring as an aid in diabetes management. Diabetes Care 1978; 1:150-7.
59. Lockhart W, Smith DH, Mair A, Wilson WA. Practical experience with the peak flow meter. Br Med J 1960; 1:37-8.
60. Brown HM. Treatment of chronic asthma with prednisolone. Significance of eosinophils in the sputum. Lancet 1958; 2:1245-7.
61. Flood-Page P, Swenson C, Faiferman I et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007; 176:1062-71.
62. Pavord ID, Korn S, Howarth P et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380:651-9.
63. Seddon P, Bara A, Ducharme FM, Lasserson TJ. Oral xanthines as maintenance treatment for asthma in children. Cochrane Database Syst Rev 2006:CD002885.
64. Castro M, Rubin AS, Laviolette M et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med 2010; 181:116-24.
65. Blakey JD, Hall IP. Current progress in pharmacogenetics. Br J Clin Pharmacol 2011; 71:824-31.
66. Wechsler ME, Castro M, Lehman E et al. Impact of race on asthma treatment failures in the asthma clinical research network. Am J Respir Crit Care Med 2011; 184:1247-53.
67. Jatakanon A, Lim S, Barnes PJ. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med 2000; 161:64-72.
68. Leuppi JD, Salome CM, Jenkins CR et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med 2001; 163:406-12.
69. Pizzichini MM, Pizzichini E, Clelland L et al. Prednisone-dependent asthma: inflammatory indices in induced sputum. Eur Respir J 1999; 13:15-21.
70. Petsky HL, Cates CJ, Lasserson TJ et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012; 67:199-208.
71. Green RH, Brightling CE, McKenna S et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360:1715-21.
72. Petsky HL, Cates CJ, Li A, Kynaston JA, Turner C, Chang AB. Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults. Cochrane Database Syst Rev (Online) 2009:CD006340.
73. Powell H, Murphy VE, Taylor DR et al. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet 2011; 378:983-90.
74. Shaw DE, Berry MA, Thomas M et al. The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. Am J Respir Crit Care Med 2007; 176:231-7.
75. Bafadhel M, McKenna S, Terry S et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2012; 186:48-55.
76. Boudier A, Curjuric I, Basagana X et al. Ten-year follow-up of cluster-based asthma phenotypes in adults. A pooled analysis of three cohorts. Am J Respir Crit Care Med 2013; 188:550-60.
77. Wenzel S, Ford L, Pearlman D et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013; 368:2455-66.
78. Corren J, Lemanske RF, Hanania NA et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365:1088-98.
79. Gotzsche PC, Johansen HK. House dust mite control measures for asthma. Cochrane Database Syst Rev 2008:CD001187.
80. Boyle RJ, Pedroletti C, Wickman M et al. Nocturnal temperature controlled laminar airflow for treating atopic asthma: a randomised controlled trial. Thorax 2012; 67:215-21.
81. Norman G, Faria FR, Paton F et al. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. J Health Technol Asess 2013; 17:1-342.
82. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010:CD001186.
83. Cates CJ, Jefferson TO, Rowe BH. Vaccines for preventing influenza in people with asthma. Cochrane Database Syst Rev 2008:CD000364.
84. Brusselle GG, Vanderstichele C, Jordens P et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 2013; 68:322-9.
85. Smith JR, Noble MJ, Musgrave S et al. The at-risk registers in severe asthma (ARRISA) study: a cluster-randomised controlled trial examining effectiveness and costs in primary care. Thorax 2012; 67:1052-60.
86. Galesic M, Garcia-Retamero R. Statistical numeracy for health: a cross-cultural comparison with probabilistic national samples. Arch Intern Med 2010; 170:462-8.
87. Woloshin S, Schwartz LM. Communicating data about the benefits and harms of treatment: a randomized trial. Ann Intern Med 2011; 155:87-96.
88. Paling J. Strategies to help patients understand risks. BMJ 2003; 327:745-8.
89. Spiegelhalter D, Pearson M, Short I. Visualizing uncertainty about the future. Science 2011; 333:1393-400.
90. Parkes G, Greenhalgh T, Griffin M, Dent R. Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ 2008; 336:598.
91. Schmaling KB, Blume A, Afari N. A randomized controlled pilot study of motivational interviewing to change attitudes about adherence to medications for asthma. J Clin Psychol Med Settings 2001; 8:167-72.
92. Raynor DK, Blenkinsopp A, Knapp P et al. A systematic review of quantitative and qualitative research on the role and effectiveness of written information available to patients about individual medicines. Health Technol Assess 2007; 11:iii, 1-160.
93. Dennis SM, Altmann DR, Lee TH. Increase in daytime symptoms is a sensitive and specific criterion for predicting corticosteroid-treated exacerbations in a clinical asthma trial. Clin Exp Allergy 2005; 35:308-12.
94. Lehtimaki L, Kankaanranta H, Saarelainen S, Turjanmaa V, Moilanen E. Increased alveolar nitric oxide concentration in asthmatic patients with nocturnal symptoms. Eur Respir J 2002; 20:841-5.
95. Skobeloff EM, Spivey WH, St Clair SS, Schoffstall JM. The influence of age and sex on asthma admissions. JAMA 1992; 268:3437-40.
96. Bousquet J, Gaugris S, Kocevar VS et al. Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the investigation of montelukast as a partner agent for complementary therapy [corrected]. Clin Exp Allergy 2005; 35:723-7.
97. Chilmonczyk BA, Salmun LM, Megathlin KN et al. Association between exposure to environmental tobacco smoke and exacerbations of asthma in children. N Engl J Med 1993; 328:1665-9.
98. Lee SL, Wong WH, Lau YL. Association between air pollution and asthma admission among children in Hong Kong. Clin Exp Allergy 2006; 36:1138-46.
99. Williams LK, Peterson EL, Wells K et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol 2011; 128:1185-91 e2.
100. Naureckas ET, Dukic V, Bao X, Rathouz P. Short-acting beta-agonist prescription fills as a marker for asthma morbidity. Chest 2005; 128:602-8.
101. Bacon SL, Bouchard A, Loucks EB, Lavoie KL. Individual-level socioeconomic status is associated with worse asthma morbidity in patients with asthma. Respir Res 2009; 10:125.
102. Sandberg S, Paton JY, Ahola S et al. The role of acute and chronic stress in asthma attacks in children. Lancet 2000; 356:982-7.
103. Cowie RL, Revitt SG, Underwood MF, Field SK. The effect of a peak flow-based action plan in the prevention of exacerbations of asthma. Chest 1997; 112:1534-8.
104. Fuhlbrigge AL, Weiss ST, Kuntz KM, Paltiel AD. Forced expiratory volume in 1 second percentage improves the classification of severity among children with asthma. Pediatrics 2006; 118:e347-55.
105. Stenius-Aarniala B, Poussa T, Kvarnstrom J, Gronlund EL, Ylikahri M, Mustajoki P. Immediate and long term effects of weight reduction in obese people with asthma: randomised controlled study. BMJ 2000; 320:827-32.
106. Magadle R, Berar-Yanay N, Weiner P. The risk of hospitalization and near-fatal and fatal asthma in relation to the perception of dyspnea. Chest 2002; 121:329-33.